Axial Biotech Raises Series B

Axial Biotech, a Salt Lake City-based developer of DNA-based pre-symptomatic and prognostic tests for common spinal disorders, has raised $15.3 million in Series B funding. Johnson & Johnson Development Corp. led the deal, and was joined by return backers vSpring Capital and Ohio Biotech Group. www.axialbiotech.com